Apitope Overview

  • Founded
  • 2002
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $13.5M
Latest Deal Amount
  • Investors
  • 10

Apitope General Information

Description

Provider of antigen-specific therapeutic peptides designed to develop novel therapeutics that directly target the underlying cause of allergy and autoimmune disease. The company's therapies are focused on the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves' disease, and Uveitis, enabling patients to enjoy a normal quality of life without the risk of secondary infection and further complications.

Contact Information

Website
www.apitope.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Primary Office
  • Agoralaan
  • Building A-bis
  • 3590 Diepenbeek
  • Belgium
+32 011 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Apitope Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 29-Sep-2015 $13.5M 000.00 Completed Generating Revenue
3. Grant 08-Jan-2014 00.000 000.00 Completed Generating Revenue
2. Grant 21-Dec-2012 $1.56M $14.9M Completed Generating Revenue
1. Later Stage VC (Series A) 09-Dec-2009 $14.9M $14.9M 000.00 Completed Generating Revenue
To view Apitope’s complete valuation and funding history, request access »

Apitope Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Category B 0,000,000 00.00 00.00 00 00.00 00.000
Category B 0,000,000 00.00 00.00 00 00.00 00.000
To view Apitope’s complete cap table history, request access »

Apitope Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of antigen-specific therapeutic peptides designed to develop novel therapeutics that directly target the underl
Drug Discovery
Diepenbeek, Belgium
6 As of 2015
000.00
00000000000 000.00

00000000

um dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
0000 000000000
Rockville, MD
0 As of 0000
000.00
0000000000 0 000.00

00000000

eniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
0000000000000
Holliston, MA
00 As of 0000
000.00
000000000 - 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Apitope Competitors (40)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytImmune Sciences Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
00000000 Private Equity-Backed Holliston, MA 00 000.00 000000000 - 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
You’re viewing 5 of 40 competitors. Get the full list »

Apitope Executive Team (9)

Name Title Board Seat Contact Info
Hayley French Ph.D Chief Executive Officer, Chief Business Officer & General Counsel
David Wraith Founder, Chief Scientific Officer & Board Member
Luc Lammens Director, Finance & Human Resource
Andrea Jahraus Ph.D Director, Operations
Liselotte Jansson Ph.D Chief Research Officer
You’re viewing 5 of 9 executive team members. Get the full list »

Apitope Board Members (11)

Name Representing Role Since
Edward Rayner Self Board Member 000 0000
Gaston Matthyssens Ph.D Vesalius Biocapital Partners Board Member 000 0000
Stéphane Verdood Vesalius Biocapital Partners Chairman 000 0000
William Jenkins Apitope Board Member 000 0000
You’re viewing 4 of 11 board members. Get the full list »

Apitope Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Apitope Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Arix Capital Management Asset Manager Minority 000 0000 000000 0
European Commission Government 000 0000 000000 0
LRM Venture Capital Minority 000 0000 000000 0
National Multiple Sclerosis Society (NMSS) Not-For-Profit Venture Capital Minority 000 0000 000000 0
PMV Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »